Compare DSL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSL | VSTM |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2013 | 2011 |
| Metric | DSL | VSTM |
|---|---|---|
| Price | $9.52 | $7.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $17.22 |
| AVG Volume (30 Days) | 793.1K | ★ 3.0M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 13.72% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $248.46 |
| Revenue Next Year | N/A | $34.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $9.61 | $3.43 |
| 52 Week High | $11.69 | $10.82 |
| Indicator | DSL | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 34.05 | 31.85 |
| Support Level | N/A | $5.26 |
| Resistance Level | $10.03 | $8.59 |
| Average True Range (ATR) | 0.11 | 0.57 |
| MACD | -0.03 | -0.31 |
| Stochastic Oscillator | 8.87 | 0.48 |
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.